| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Emergent BioSolutions Inc (NYSE: EBS)
EBS Technical Analysis
4
| As on 2nd Apr 2025 EBS STOCK Price closed @ 5.17 and we RECOMMEND Buy for LONG-TERM with Stoploss of 4.49 & Strong Buy for SHORT-TERM with Stoploss of 2.25 we also expect STOCK to react on Following IMPORTANT LEVELS. |
EBSSTOCK Price
| Open | 4.62 | Change | Price | % |
| High | 5.35 | 1 Day | 0.43 | 9.07 |
| Low | 4.62 | 1 Week | -0.56 | -9.77 |
| Close | 5.17 | 1 Month | -2.80 | -35.13 |
| Volume | 1927382 | 1 Year | 2.65 | 105.16 |
| 52 Week High 14.77 | 52 Week Low 1.50 | ||||
NYSE USA Most Active Stocks
| FSR | 0.02 | 0.00% |
| DDR | 15.44 | -4.46% |
| TWTR | 53.70 | 0.66% |
| F | 10.15 | 2.11% |
| SWN | 7.11 | -0.56% |
| BACA-U | 302.00 | 0.67% |
| ENLC | 14.12 | -0.21% |
| PLTR | 87.45 | 3.27% |
| RIG | 3.16 | -4.82% |
| RPAI | 13.15 | -3.17% |
NYSE USA Top Gainers Stocks
NYSE USA Top Losers Stocks
| EBS Daily Charts |
EBS Intraday Charts |
Whats New @ Bazaartrend |
EBS Free Analysis |
|
|
EBS Important Levels Intraday
| RESISTANCE | 6.58 |
| RESISTANCE | 6.13 |
| RESISTANCE | 5.85 |
| RESISTANCE | 5.57 |
| SUPPORT | 4.77 |
| SUPPORT | 4.49 |
| SUPPORT | 4.21 |
| SUPPORT | 3.76 |
EBS Forecast April 2025
| 4th UP Forecast | 6.62 |
| 3rd UP Forecast | 6.15 |
| 2nd UP Forecast | 5.87 |
| 1st UP Forecast | 5.58 |
| 1st DOWN Forecast | 4.76 |
| 2nd DOWN Forecast | 4.47 |
| 3rd DOWN Forecast | 4.19 |
| 4th DOWN Forecast | 3.72 |
EBS Weekly Forecast
| 4th UP Forecast | 6.06 |
| 3rd UP Forecast | 5.77 |
| 2nd UP Forecast | 5.60 |
| 1st UP Forecast | 5.42 |
| 1st DOWN Forecast | 4.92 |
| 2nd DOWN Forecast | 4.74 |
| 3rd DOWN Forecast | 4.57 |
| 4th DOWN Forecast | 4.28 |
EBS Forecast2025
| 4th UP Forecast | 31.53 |
| 3rd UP Forecast | 23.08 |
| 2nd UP Forecast | 17.85 |
| 1st UP Forecast | 12.63 |
| 1st DOWN Forecast | -2.29 |
| 2nd DOWN Forecast | -7.51 |
| 3rd DOWN Forecast | -12.74 |
| 4th DOWN Forecast | -21.19 |
Emergent BioSolutions Inc ( NYSE USA Symbol : EBS )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
EBS Business Profile
Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response products and solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs). The company's products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; and emerging health crises and acute/emergency care. It offers ACAM2000, a smallpox vaccine; BioThrax, an anthrax vaccine; Vaxchora, a cholera vaccine; and Vivotif, a typhoid vaccine. The company also provides NARCAN for the emergency treatment of known or suspected opioid overdose; and Reactive Skin Decontamination Lotion Kit. In addition, it offers raxibacumab for the treatment and prophylaxis of inhalational anthrax; Anthrasil to treat inhalational anthrax; Botulism Antitoxin Heptavalent for treating botulinum disease; vaccinia immune globulin intravenous that addresses complications from smallpox vaccine; and Trobigard, a combination drug-device auto injector product candidate. Further, the company is developing COVID-EIG and COVID-HIG for the treatment of SARS-CoV-2; FLU-IGIV for the treatment of seasonal influenza A virus; AV7909, an anthrax vaccine candidate; CHIKV VLP, a chikungunya virus VLP vaccine; ZIKV-IG, a zika therapeutic candidate; Shigella-ETEC, a shigella vaccine expressing ETEC antigens; EBS-LASV, a vector vaccine for Lassa fever; UNI-FLU, a universal influenza vaccine; rVSV-Marburg, a vector vaccine for treatment of Marburg virus disease; rVSV-Sudan, a vector vaccine for treatment of Sudan virus disease; DAT, a diphtheria antitoxin; Ricin-IG, a ricin antitoxin; and Pan-Ebola, a Ebola/Sudan monoclonal. Additionally, it provides contract development and manufacturing service that comprises development services, drug substance manufacturing, and drug product manufacturing. Emergent BioSolutions Inc. was incorporated in 1998 and is headquartered in Gaithersburg, Maryland. Address: 400 Professional Drive, Gaithersburg, MD, United States, 20879
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service